Navigation Links
ForSight Labs, LLC Announces Formation of Its Third Company, ForSight VISION3, Inc. and Closing of $6 Million in Series A Funding
Date:1/7/2008

MENLO PARK, Calif., Jan. 7 /PRNewswire/ -- ForSight Labs, LLC announced today the formation and funding of its third company, ForSight VISION3, Inc. with a Series A financing of $6 million, supported by three of the leading venture capital firms in the medical technology arena: Morgenthaler Ventures, Split Rock Partners and Versant Ventures.

"We are excited to have closed a significant round of funding to develop our next innovative ophthalmic technology," said K. Angela Macfarlane, President and CEO of ForSight VISION3. "The ForSight team is already assessing dramatic new opportunities."

The existing ForSight VISION companies, Transcend Medical, and ForSight Newco II (now a wholly owned subsidiary of QLT, Inc.) have each developed high impact products for major ophthalmic markets.

"Ophthalmology continues to have a considerable need for new technologies to address vision loss in all market segments," said Eugene de Juan, Jr. MD, Founder and Vice Chairman of ForSight Labs. "ForSight VISION3 is well positioned to carefully select and develop successful product solutions." Each of the venture partnerships will take a seat on the ForSight VISION3 Board of Directors.

About ForSight Labs, LLC

ForSight Labs is a community of ophthalmic innovation focused on improving the sight, care, and quality of life of visually impaired patients by creating high-impact eye care companies (http://www.forsightlabs.com). ForSight Labs, LLC was established in 2005 by renowned ophthalmologist and retinal surgeon Eugene de Juan, Jr. MD in collaboration with The Foundry (http://www.thefoundry.com). In late 2006, ForSight Labs launched its first company, Transcend Medical, Inc. In October 2007, its second spin out company ForSight Newco II, Inc., developing a proprietary ocular punctal plug drug delivery system, was acquired by QLT Inc. (Nasdaq: QLTI; TSX: QLT). ForSight Labs is backed by investors Morgenthaler Ventures (http://www.morgenthaler.com), Split Rock Partners (http://www.splitrock.com), and Versant Ventures (http://www.versantventures.com).

About Morgenthaler Ventures

Morgenthaler Ventures is a leading, national venture capital team with offices in Menlo Park, CA; Boston, MA; Princeton, NJ, Boulder, CO; and Cleveland, OH. It concentrates its investments in life sciences and information technology.

Morgenthaler's Life Science Team focuses on medical devices and therapeutic pharmaceuticals. Recent investments include Avidia, Morphotek, Threshold Pharmaceuticals, Replidyne, Orexigen, Thermage, Emphasys, Satiety, Cierra, Ardian, Cabochon Aesthetics, Transcend and Xtent. The firm has approximately $2.5 billion under management and has funded more than 250 companies since 1968. For more information on Morgenthaler portfolio companies and the firm, please visit: http://www.morgenthaler.com/ventures.

About Split Rock Partners

Split Rock Partners, with offices in Menlo Park and Minneapolis, invests in emerging opportunities in healthcare and internet services primarily on the West Coast and the Upper Midwest. Split Rock Partners was formed in June, 2004 by the healthcare and software investment teams of St. Paul Venture Capital. In April, 2005, Split Rock announced the closing of a new $275 million venture fund. Split Rock Partners' portfolio of healthcare investments has included such industry leading companies as SpineTech, The Foundry, Dexcom, Emphasys Medical, Xtent, Atritech, Prometheus Labs, and many others. Additional information about the firm can be found at http://www.splitrock.com.

About Versant Ventures

Founded in 1999, Versant Ventures is a leading healthcare venture capital firm that currently manages over $1 billion in committed capital. Since its formation, Versant has invested in more than 75 companies in the Medical Device, Biotech, Healthcare Services and Healthcare Information Technology sectors. The Versant team of twelve investment professionals located in Menlo Park and Newport Beach bring together more than 175 years of combined experience and success as venture capitalists and entrepreneurs. Versant invests in early-stage healthcare companies promising to be significant, long-term market leaders. For additional information, please visit http://www.versantventures.com.


'/>"/>
SOURCE ForSight Labs, LLC
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. QLT Completes Acquisition of ForSight Newco II, Inc.
2. ForSight Labs Announces Acquisition of ForSight Newco II by QLT, Inc.
3. QLT acquires leading edge ocular drug delivery system from ForSight Labs
4. Barc Announces New Travel Size for Its Razor Bump Relief Product
5. Immucor Announces Update to Second Quarter Conference Call Number
6. New Poll Announces Link Between Friends and Family Influence and a Healthy Lifestyle
7. Kensey Nash Corporation Announces Its Second Quarter 2008 Earnings Release Date and Teleconference
8. QED International Associates Announces Changes to the HealthShares(TM) Emerging Cancer Index
9. BD Announces Live Webcast of First Fiscal Quarter Earnings Conference Call
10. amfAR announces inaugural Mathilde Krim Fellowship Awards for AIDS research
11. Torchmark Corporation Announces Change in Domicile State of Insurance Subsidiaries to Nebraska
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... ... Brent Kasmer, a legally blind and certified personal trainer is helping to develop a weight ... app plans to fix the two major problems leading the fitness industry today:, ... program , They don’t eliminate all the reasons people quit their exercise program ...
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from the American ... Annual Research Meeting June 26-28, 2016, at the Hynes Convention Center in Boston. ... including advance care planning, healthcare costs and patient and family engagement. , AIR ...
(Date:6/25/2016)... ... ... closing of Bruton Memorial Library on June 21 due to a possible lice infestation, as ... of head lice: the parasite’s ability to live away from a human host, and to ... one in the event that lice have simply gotten out of control. , As lice ...
(Date:6/25/2016)... Lewisville, TX (PRWEB) , ... June 25, 2016 , ... ... in the United States, named Dr. Sesan Ogunleye, as the Medical Director of its ... be the facility Medical Director of our new Mesquite location,” said Dr. James M. ...
(Date:6/25/2016)... ... 25, 2016 , ... Dr. Calvin Johnson has dedicated his ... implemented orthobiologic procedures as a method for treating his patients. The procedure is ... to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use to help ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)...  In a startling report released today, National Safety Council ... a comprehensive, proven plan to eliminate prescription opioid overdoses. ... states are tackling the worst drug crisis in recorded U.S. history, ... Kentucky , New Mexico , ... the 28 failing states, three – Michigan , ...
(Date:6/23/2016)... 2016 Bracket , a leading clinical trial ... clinical outcomes platform, Bracket eCOA (SM) 6.0, at the ... – 30, 2016 in Philadelphia , Pennsylvania.  ... Assessment product of its kind to fully integrate with RTSM, ... eCOA 6.0 is a flexible platform for electronic clinical outcomes ...
(Date:6/23/2016)...  Guerbet announced today that it has been named ... . One of 12 suppliers to receive ... support of Premier members through exceptional local customer service ... to lower costs. ... outstanding customer service from Premier," says Massimo Carrara ...
Breaking Medicine Technology: